MedTrace Logo

Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.

NCT06485232 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-01-01

No results posted yet for this study

Summary

This is an open label, single-site, dose-escalation study in up to 25 participants with refractory autoimmune diseases of nervous system. This study aims to evaluate the safety and efficacy of the treatment with universal BCMA and CD19 CART.

Conditions

  • Neuromyelitis Optica Spectrum Disorders
  • Myasthenia Gravis, Generalized
  • Multiple Sclerosis
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Interventions

DRUG

Universal BCMA CAR-T

Universal BCMA CAR-T

DRUG

Universal CD19 CAR-T

Universal CD19 CAR-T

DRUG

Universal BCMA CAR-T; Universal CD19 CAR-T

Universal BCMA CAR-T; Universal CD19 CAR-T

Sponsors & Collaborators

  • Bioray Laboratories

    collaborator INDUSTRY

  • Xuanwu Hospital, Beijing

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-28
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06485232 on ClinicalTrials.gov